(CercleFinance.com) – Valneva publishes a net profit of 58.9 million euros for the first three months of 2024, reflecting the sale of the priority review voucher (PRV), compared to a loss of 18.1 million a year earlier , its adjusted EBITDA having increased from -12.3 to +73 million.
The vaccine company saw its total turnover fall by 2% to 32.8 million euros with product sales stable at 32.1 million, including 16.6 million for Ixiaro/Jespect (Japanese encephalitis) and 11.3 million for Dukoral (cholera).
Valneva confirms that for the current year it is forecasting a total turnover estimated between 170 and 190 million euros, including 160 to 180 million in sales thanks to the growth in sales of the vaccines it owns.
‘For the rest of the year, we plan to continue to benefit from the recovery of the travel industry and at the same time achieve the various R&D milestones that we have set for ourselves,’ says its financial director Peter Bühler.